Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study
ANA profiles vary across tumor types and differ between treatment-naïve and ICI-treated patients. CTLA-4-treated patients exhibit higher ANA frequency. Different tumors exhibit distinct preferences for AAb expression patterns. Serum AAb profiling may serve as a valuable tool for immunotherapy monitoring and risk stratification for immune-related adverse events.
Authors
- R. Liu
- Juan Wang (ORCID: https://orcid.org/0000-0003-0767-5687)
- Chen Zhang (ORCID: https://orcid.org/0000-0002-5279-7512)
- Kun Chen (ORCID: https://orcid.org/0000-0003-4231-4502)
- Baoliang Guo (ORCID: https://orcid.org/0000-0002-4022-6739)
- Guobing Xu
Institutions
- Ministry of Education (ET)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-24
- DOI
- https://doi.org/10.3389/fonc.2025.1716014
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00